Chimeric Therapeutics (ASX: CHM) secures ethics approval to start CHM CDH17 Phase 1/2 clinical trial

May 19, 2024 06:13 PM PDT | By Sonal Goyal

Recent News

My 3M stock price forecast was correct: now what?

Short USD/CHF: market trend indicates the price is likely to drop furt...

Lamb Weston had a disappointing Q2: what the French fries economics is...

Solympics and Bitbot lead crypto surge with record growth and cutting-...

Highlights

Ethics approval received to start CHM CDH17 Phase 1/2 clinical trial.

The study will be conducted on patients with advanced gastrointestinal (GI) cancers.

In earlier studies, CHM CDH17 eradicated established tumours in seven cancer models.

Chimeric Therapeutics Limited (ASX: CHM) has achieved a significant milestone with the receipt of ethics approval to commence a multi-site Phase 1/2 clinical trial of CHM CDH17. The trial will focus on patients with advanced gastrointestinal (GI) cancers.

This development marks a significant step forward in initiating the clinical trial under the FDA (Food and Drug Administration) regulations, highlights the company.

About CHM CDH17

CHM CDH17 is a third generation CAR T cell therapy, which is designed to target CDH17, a cancer target linked with poor metastasis and prognosis in the gastrointestinal tumours, such as neuroendocrine tumours, gastric and colorectal cancers.

Image source: Company update

This year, the company intends to undertake Phase 1A trial in neuroendocrine and gastrointestinal tumours.

CHM shares jump

Triggered by the update, CHM shares jumped by over 14% to AU$0.024 apiece during the early morning trading hours on 20 May 2024.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.